Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2014
Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study.
Erratum issued Registry-linked trialAbstract readClinical Trial, Phase IIIComparative StudyMulticenter Study
In one paragraph
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02870036 (Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients With Advanced Solid Tumors), which is not on this map. Cited by 115 papers, 10 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
115citing papers in PubMed, 10 pooled it
22.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients With Advanced Solid Tumors
Who cites it
115 citing papers in PubMed, 10 syntheses or guidelines pooled it, 258 citations in OpenAlex.
- Updated German guideline on diagnosis and treatment of squamous cell carcinoma and adenocarcinoma of the esophagus.United European gastroenterology journal · 2024Guideline
- Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma.The oncologist · 2021Pooled it
- Treatment Strategies of Gastric Cancer-Molecular Targets for Anti-angiogenic Therapy: a State-of-the-art Review.Journal of gastrointestinal cancer · 2021Pooled it
- Time to deterioration in cancer randomized clinical trials for patient-reported outcomes data: a systematic review.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2020Pooled it
- Consensus statement of the Hellenic and Cypriot Oesophageal Cancer Study Group on the diagnosis, staging and management of oesophageal cancer.Updates in surgery · 2019Guideline
- Pooled it
- Reporting of health-related quality of life in randomized controlled trials involving palliative systemic therapy for esophagogastric cancer: a systematic review.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2018Pooled it
- Chemotherapy for advanced gastric cancer.The Cochrane database of systematic reviews · 2017Pooled it
- A Bayesian network meta-analysis on second-line systemic therapy in advanced gastric cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2017Pooled it
- Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis.Cancer metastasis reviews · 2015Pooled it
- Envafolimab combined with lenvatinib and albumin-bound paclitaxel in previously treated advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: a prospective, phase II, multi-cohort trial.Cancer immunology, immunotherapy : CII · 2026Trial
- Trial
- Trial
- Trial
- Trial
- Trial
- XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer: An open-labeled, multicenter, randomized, prospective phase III trial (EXELOX).Cancer communications (London, England) · 2022Trial
- HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial.Journal for immunotherapy of cancer · 2020Trial
- FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial.JAMA oncology · 2020Trial
- Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2019Trial
55 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Erratum issuedErrata.2015
Authors and funding
17 authors at 1 institution in 1 country.
Rosine GuimbaudRosine Guimbaud, Centre Hospitalier Universitaire Toulouse, Toulouse; Christophe Louvet, Institut Mutualiste Montsouris; Thierry André, Hôpital Saint Antoine; Jean-Marc Gornet, Centre Hospitalier Universitaire Saint Louis (Assistance Publique-Hôpitaux de Paris); Pascal Hammel, Hôpital Beaujon; Philippe Rougier, Hôpital Européen Georges Pompidou, Paris; Pauline Ries, Institut Paoli Calmettes, Marseille; Marc Ychou, Institut Régional du Cancer Val d'Aurelle, Montpellier; Emilie Maillard, Fédération Francophone de Cancérologie Digestive; Laurent Bedenne, Centre Hospitalier Universitaire, Dijon; Thomas Aparicio, Hôpital Avicenne, Bobigny; Suzanne Nguyen, Hôpital Général, Beauvais; Ahmed Azzedine, Hôpital Général, Montélimard; Pierre-Luc Etienne, Clinique Armoricaine, Saint-Brieuc; Eveline Boucher, Centre Eugène Marquis, Rennes; Christine Rebischung, Hôpital A. Michallon, Grenoble; Olivier Bouché, Centre Hospitalier Universitaire Robert Debré, Reims, France. guimbaud.r@chu-toulouse.fr.
Christophe LouvetRosine Guimbaud, Centre Hospitalier Universitaire Toulouse, Toulouse; Christophe Louvet, Institut Mutualiste Montsouris; Thierry André, Hôpital Saint Antoine; Jean-Marc Gornet, Centre Hospitalier Universitaire Saint Louis (Assistance Publique-Hôpitaux de Paris); Pascal Hammel, Hôpital Beaujon; Philippe Rougier, Hôpital Européen Georges Pompidou, Paris; Pauline Ries, Institut Paoli Calmettes, Marseille; Marc Ychou, Institut Régional du Cancer Val d'Aurelle, Montpellier; Emilie Maillard, Fédération Francophone de Cancérologie Digestive; Laurent Bedenne, Centre Hospitalier Universitaire, Dijon; Thomas Aparicio, Hôpital Avicenne, Bobigny; Suzanne Nguyen, Hôpital Général, Beauvais; Ahmed Azzedine, Hôpital Général, Montélimard; Pierre-Luc Etienne, Clinique Armoricaine, Saint-Brieuc; Eveline Boucher, Centre Eugène Marquis, Rennes; Christine Rebischung, Hôpital A. Michallon, Grenoble; Olivier Bouché, Centre Hospitalier Universitaire Robert Debré, Reims, France.
Pauline RiesRosine Guimbaud, Centre Hospitalier Universitaire Toulouse, Toulouse; Christophe Louvet, Institut Mutualiste Montsouris; Thierry André, Hôpital Saint Antoine; Jean-Marc Gornet, Centre Hospitalier Universitaire Saint Louis (Assistance Publique-Hôpitaux de Paris); Pascal Hammel, Hôpital Beaujon; Philippe Rougier, Hôpital Européen Georges Pompidou, Paris; Pauline Ries, Institut Paoli Calmettes, Marseille; Marc Ychou, Institut Régional du Cancer Val d'Aurelle, Montpellier; Emilie Maillard, Fédération Francophone de Cancérologie Digestive; Laurent Bedenne, Centre Hospitalier Universitaire, Dijon; Thomas Aparicio, Hôpital Avicenne, Bobigny; Suzanne Nguyen, Hôpital Général, Beauvais; Ahmed Azzedine, Hôpital Général, Montélimard; Pierre-Luc Etienne, Clinique Armoricaine, Saint-Brieuc; Eveline Boucher, Centre Eugène Marquis, Rennes; Christine Rebischung, Hôpital A. Michallon, Grenoble; Olivier Bouché, Centre Hospitalier Universitaire Robert Debré, Reims, France.
Marc YchouRosine Guimbaud, Centre Hospitalier Universitaire Toulouse, Toulouse; Christophe Louvet, Institut Mutualiste Montsouris; Thierry André, Hôpital Saint Antoine; Jean-Marc Gornet, Centre Hospitalier Universitaire Saint Louis (Assistance Publique-Hôpitaux de Paris); Pascal Hammel, Hôpital Beaujon; Philippe Rougier, Hôpital Européen Georges Pompidou, Paris; Pauline Ries, Institut Paoli Calmettes, Marseille; Marc Ychou, Institut Régional du Cancer Val d'Aurelle, Montpellier; Emilie Maillard, Fédération Francophone de Cancérologie Digestive; Laurent Bedenne, Centre Hospitalier Universitaire, Dijon; Thomas Aparicio, Hôpital Avicenne, Bobigny; Suzanne Nguyen, Hôpital Général, Beauvais; Ahmed Azzedine, Hôpital Général, Montélimard; Pierre-Luc Etienne, Clinique Armoricaine, Saint-Brieuc; Eveline Boucher, Centre Eugène Marquis, Rennes; Christine Rebischung, Hôpital A. Michallon, Grenoble; Olivier Bouché, Centre Hospitalier Universitaire Robert Debré, Reims, France.
Emilie MaillardRosine Guimbaud, Centre Hospitalier Universitaire Toulouse, Toulouse; Christophe Louvet, Institut Mutualiste Montsouris; Thierry André, Hôpital Saint Antoine; Jean-Marc Gornet, Centre Hospitalier Universitaire Saint Louis (Assistance Publique-Hôpitaux de Paris); Pascal Hammel, Hôpital Beaujon; Philippe Rougier, Hôpital Européen Georges Pompidou, Paris; Pauline Ries, Institut Paoli Calmettes, Marseille; Marc Ychou, Institut Régional du Cancer Val d'Aurelle, Montpellier; Emilie Maillard, Fédération Francophone de Cancérologie Digestive; Laurent Bedenne, Centre Hospitalier Universitaire, Dijon; Thomas Aparicio, Hôpital Avicenne, Bobigny; Suzanne Nguyen, Hôpital Général, Beauvais; Ahmed Azzedine, Hôpital Général, Montélimard; Pierre-Luc Etienne, Clinique Armoricaine, Saint-Brieuc; Eveline Boucher, Centre Eugène Marquis, Rennes; Christine Rebischung, Hôpital A. Michallon, Grenoble; Olivier Bouché, Centre Hospitalier Universitaire Robert Debré, Reims, France.
Thierry AndréRosine Guimbaud, Centre Hospitalier Universitaire Toulouse, Toulouse; Christophe Louvet, Institut Mutualiste Montsouris; Thierry André, Hôpital Saint Antoine; Jean-Marc Gornet, Centre Hospitalier Universitaire Saint Louis (Assistance Publique-Hôpitaux de Paris); Pascal Hammel, Hôpital Beaujon; Philippe Rougier, Hôpital Européen Georges Pompidou, Paris; Pauline Ries, Institut Paoli Calmettes, Marseille; Marc Ychou, Institut Régional du Cancer Val d'Aurelle, Montpellier; Emilie Maillard, Fédération Francophone de Cancérologie Digestive; Laurent Bedenne, Centre Hospitalier Universitaire, Dijon; Thomas Aparicio, Hôpital Avicenne, Bobigny; Suzanne Nguyen, Hôpital Général, Beauvais; Ahmed Azzedine, Hôpital Général, Montélimard; Pierre-Luc Etienne, Clinique Armoricaine, Saint-Brieuc; Eveline Boucher, Centre Eugène Marquis, Rennes; Christine Rebischung, Hôpital A. Michallon, Grenoble; Olivier Bouché, Centre Hospitalier Universitaire Robert Debré, Reims, France.
Jean-Marc GornetRosine Guimbaud, Centre Hospitalier Universitaire Toulouse, Toulouse; Christophe Louvet, Institut Mutualiste Montsouris; Thierry André, Hôpital Saint Antoine; Jean-Marc Gornet, Centre Hospitalier Universitaire Saint Louis (Assistance Publique-Hôpitaux de Paris); Pascal Hammel, Hôpital Beaujon; Philippe Rougier, Hôpital Européen Georges Pompidou, Paris; Pauline Ries, Institut Paoli Calmettes, Marseille; Marc Ychou, Institut Régional du Cancer Val d'Aurelle, Montpellier; Emilie Maillard, Fédération Francophone de Cancérologie Digestive; Laurent Bedenne, Centre Hospitalier Universitaire, Dijon; Thomas Aparicio, Hôpital Avicenne, Bobigny; Suzanne Nguyen, Hôpital Général, Beauvais; Ahmed Azzedine, Hôpital Général, Montélimard; Pierre-Luc Etienne, Clinique Armoricaine, Saint-Brieuc; Eveline Boucher, Centre Eugène Marquis, Rennes; Christine Rebischung, Hôpital A. Michallon, Grenoble; Olivier Bouché, Centre Hospitalier Universitaire Robert Debré, Reims, France.
Thomas AparicioRosine Guimbaud, Centre Hospitalier Universitaire Toulouse, Toulouse; Christophe Louvet, Institut Mutualiste Montsouris; Thierry André, Hôpital Saint Antoine; Jean-Marc Gornet, Centre Hospitalier Universitaire Saint Louis (Assistance Publique-Hôpitaux de Paris); Pascal Hammel, Hôpital Beaujon; Philippe Rougier, Hôpital Européen Georges Pompidou, Paris; Pauline Ries, Institut Paoli Calmettes, Marseille; Marc Ychou, Institut Régional du Cancer Val d'Aurelle, Montpellier; Emilie Maillard, Fédération Francophone de Cancérologie Digestive; Laurent Bedenne, Centre Hospitalier Universitaire, Dijon; Thomas Aparicio, Hôpital Avicenne, Bobigny; Suzanne Nguyen, Hôpital Général, Beauvais; Ahmed Azzedine, Hôpital Général, Montélimard; Pierre-Luc Etienne, Clinique Armoricaine, Saint-Brieuc; Eveline Boucher, Centre Eugène Marquis, Rennes; Christine Rebischung, Hôpital A. Michallon, Grenoble; Olivier Bouché, Centre Hospitalier Universitaire Robert Debré, Reims, France.
Suzanne NguyenRosine Guimbaud, Centre Hospitalier Universitaire Toulouse, Toulouse; Christophe Louvet, Institut Mutualiste Montsouris; Thierry André, Hôpital Saint Antoine; Jean-Marc Gornet, Centre Hospitalier Universitaire Saint Louis (Assistance Publique-Hôpitaux de Paris); Pascal Hammel, Hôpital Beaujon; Philippe Rougier, Hôpital Européen Georges Pompidou, Paris; Pauline Ries, Institut Paoli Calmettes, Marseille; Marc Ychou, Institut Régional du Cancer Val d'Aurelle, Montpellier; Emilie Maillard, Fédération Francophone de Cancérologie Digestive; Laurent Bedenne, Centre Hospitalier Universitaire, Dijon; Thomas Aparicio, Hôpital Avicenne, Bobigny; Suzanne Nguyen, Hôpital Général, Beauvais; Ahmed Azzedine, Hôpital Général, Montélimard; Pierre-Luc Etienne, Clinique Armoricaine, Saint-Brieuc; Eveline Boucher, Centre Eugène Marquis, Rennes; Christine Rebischung, Hôpital A. Michallon, Grenoble; Olivier Bouché, Centre Hospitalier Universitaire Robert Debré, Reims, France.
Ahmed AzzedineRosine Guimbaud, Centre Hospitalier Universitaire Toulouse, Toulouse; Christophe Louvet, Institut Mutualiste Montsouris; Thierry André, Hôpital Saint Antoine; Jean-Marc Gornet, Centre Hospitalier Universitaire Saint Louis (Assistance Publique-Hôpitaux de Paris); Pascal Hammel, Hôpital Beaujon; Philippe Rougier, Hôpital Européen Georges Pompidou, Paris; Pauline Ries, Institut Paoli Calmettes, Marseille; Marc Ychou, Institut Régional du Cancer Val d'Aurelle, Montpellier; Emilie Maillard, Fédération Francophone de Cancérologie Digestive; Laurent Bedenne, Centre Hospitalier Universitaire, Dijon; Thomas Aparicio, Hôpital Avicenne, Bobigny; Suzanne Nguyen, Hôpital Général, Beauvais; Ahmed Azzedine, Hôpital Général, Montélimard; Pierre-Luc Etienne, Clinique Armoricaine, Saint-Brieuc; Eveline Boucher, Centre Eugène Marquis, Rennes; Christine Rebischung, Hôpital A. Michallon, Grenoble; Olivier Bouché, Centre Hospitalier Universitaire Robert Debré, Reims, France.
Pierre-Luc EtienneRosine Guimbaud, Centre Hospitalier Universitaire Toulouse, Toulouse; Christophe Louvet, Institut Mutualiste Montsouris; Thierry André, Hôpital Saint Antoine; Jean-Marc Gornet, Centre Hospitalier Universitaire Saint Louis (Assistance Publique-Hôpitaux de Paris); Pascal Hammel, Hôpital Beaujon; Philippe Rougier, Hôpital Européen Georges Pompidou, Paris; Pauline Ries, Institut Paoli Calmettes, Marseille; Marc Ychou, Institut Régional du Cancer Val d'Aurelle, Montpellier; Emilie Maillard, Fédération Francophone de Cancérologie Digestive; Laurent Bedenne, Centre Hospitalier Universitaire, Dijon; Thomas Aparicio, Hôpital Avicenne, Bobigny; Suzanne Nguyen, Hôpital Général, Beauvais; Ahmed Azzedine, Hôpital Général, Montélimard; Pierre-Luc Etienne, Clinique Armoricaine, Saint-Brieuc; Eveline Boucher, Centre Eugène Marquis, Rennes; Christine Rebischung, Hôpital A. Michallon, Grenoble; Olivier Bouché, Centre Hospitalier Universitaire Robert Debré, Reims, France.
Eveline BoucherRosine Guimbaud, Centre Hospitalier Universitaire Toulouse, Toulouse; Christophe Louvet, Institut Mutualiste Montsouris; Thierry André, Hôpital Saint Antoine; Jean-Marc Gornet, Centre Hospitalier Universitaire Saint Louis (Assistance Publique-Hôpitaux de Paris); Pascal Hammel, Hôpital Beaujon; Philippe Rougier, Hôpital Européen Georges Pompidou, Paris; Pauline Ries, Institut Paoli Calmettes, Marseille; Marc Ychou, Institut Régional du Cancer Val d'Aurelle, Montpellier; Emilie Maillard, Fédération Francophone de Cancérologie Digestive; Laurent Bedenne, Centre Hospitalier Universitaire, Dijon; Thomas Aparicio, Hôpital Avicenne, Bobigny; Suzanne Nguyen, Hôpital Général, Beauvais; Ahmed Azzedine, Hôpital Général, Montélimard; Pierre-Luc Etienne, Clinique Armoricaine, Saint-Brieuc; Eveline Boucher, Centre Eugène Marquis, Rennes; Christine Rebischung, Hôpital A. Michallon, Grenoble; Olivier Bouché, Centre Hospitalier Universitaire Robert Debré, Reims, France.
Christine RebischungRosine Guimbaud, Centre Hospitalier Universitaire Toulouse, Toulouse; Christophe Louvet, Institut Mutualiste Montsouris; Thierry André, Hôpital Saint Antoine; Jean-Marc Gornet, Centre Hospitalier Universitaire Saint Louis (Assistance Publique-Hôpitaux de Paris); Pascal Hammel, Hôpital Beaujon; Philippe Rougier, Hôpital Européen Georges Pompidou, Paris; Pauline Ries, Institut Paoli Calmettes, Marseille; Marc Ychou, Institut Régional du Cancer Val d'Aurelle, Montpellier; Emilie Maillard, Fédération Francophone de Cancérologie Digestive; Laurent Bedenne, Centre Hospitalier Universitaire, Dijon; Thomas Aparicio, Hôpital Avicenne, Bobigny; Suzanne Nguyen, Hôpital Général, Beauvais; Ahmed Azzedine, Hôpital Général, Montélimard; Pierre-Luc Etienne, Clinique Armoricaine, Saint-Brieuc; Eveline Boucher, Centre Eugène Marquis, Rennes; Christine Rebischung, Hôpital A. Michallon, Grenoble; Olivier Bouché, Centre Hospitalier Universitaire Robert Debré, Reims, France.
Pascal HammelRosine Guimbaud, Centre Hospitalier Universitaire Toulouse, Toulouse; Christophe Louvet, Institut Mutualiste Montsouris; Thierry André, Hôpital Saint Antoine; Jean-Marc Gornet, Centre Hospitalier Universitaire Saint Louis (Assistance Publique-Hôpitaux de Paris); Pascal Hammel, Hôpital Beaujon; Philippe Rougier, Hôpital Européen Georges Pompidou, Paris; Pauline Ries, Institut Paoli Calmettes, Marseille; Marc Ychou, Institut Régional du Cancer Val d'Aurelle, Montpellier; Emilie Maillard, Fédération Francophone de Cancérologie Digestive; Laurent Bedenne, Centre Hospitalier Universitaire, Dijon; Thomas Aparicio, Hôpital Avicenne, Bobigny; Suzanne Nguyen, Hôpital Général, Beauvais; Ahmed Azzedine, Hôpital Général, Montélimard; Pierre-Luc Etienne, Clinique Armoricaine, Saint-Brieuc; Eveline Boucher, Centre Eugène Marquis, Rennes; Christine Rebischung, Hôpital A. Michallon, Grenoble; Olivier Bouché, Centre Hospitalier Universitaire Robert Debré, Reims, France.
Philippe RougierRosine Guimbaud, Centre Hospitalier Universitaire Toulouse, Toulouse; Christophe Louvet, Institut Mutualiste Montsouris; Thierry André, Hôpital Saint Antoine; Jean-Marc Gornet, Centre Hospitalier Universitaire Saint Louis (Assistance Publique-Hôpitaux de Paris); Pascal Hammel, Hôpital Beaujon; Philippe Rougier, Hôpital Européen Georges Pompidou, Paris; Pauline Ries, Institut Paoli Calmettes, Marseille; Marc Ychou, Institut Régional du Cancer Val d'Aurelle, Montpellier; Emilie Maillard, Fédération Francophone de Cancérologie Digestive; Laurent Bedenne, Centre Hospitalier Universitaire, Dijon; Thomas Aparicio, Hôpital Avicenne, Bobigny; Suzanne Nguyen, Hôpital Général, Beauvais; Ahmed Azzedine, Hôpital Général, Montélimard; Pierre-Luc Etienne, Clinique Armoricaine, Saint-Brieuc; Eveline Boucher, Centre Eugène Marquis, Rennes; Christine Rebischung, Hôpital A. Michallon, Grenoble; Olivier Bouché, Centre Hospitalier Universitaire Robert Debré, Reims, France.
Laurent BedenneRosine Guimbaud, Centre Hospitalier Universitaire Toulouse, Toulouse; Christophe Louvet, Institut Mutualiste Montsouris; Thierry André, Hôpital Saint Antoine; Jean-Marc Gornet, Centre Hospitalier Universitaire Saint Louis (Assistance Publique-Hôpitaux de Paris); Pascal Hammel, Hôpital Beaujon; Philippe Rougier, Hôpital Européen Georges Pompidou, Paris; Pauline Ries, Institut Paoli Calmettes, Marseille; Marc Ychou, Institut Régional du Cancer Val d'Aurelle, Montpellier; Emilie Maillard, Fédération Francophone de Cancérologie Digestive; Laurent Bedenne, Centre Hospitalier Universitaire, Dijon; Thomas Aparicio, Hôpital Avicenne, Bobigny; Suzanne Nguyen, Hôpital Général, Beauvais; Ahmed Azzedine, Hôpital Général, Montélimard; Pierre-Luc Etienne, Clinique Armoricaine, Saint-Brieuc; Eveline Boucher, Centre Eugène Marquis, Rennes; Christine Rebischung, Hôpital A. Michallon, Grenoble; Olivier Bouché, Centre Hospitalier Universitaire Robert Debré, Reims, France.
Olivier BouchéRosine Guimbaud, Centre Hospitalier Universitaire Toulouse, Toulouse; Christophe Louvet, Institut Mutualiste Montsouris; Thierry André, Hôpital Saint Antoine; Jean-Marc Gornet, Centre Hospitalier Universitaire Saint Louis (Assistance Publique-Hôpitaux de Paris); Pascal Hammel, Hôpital Beaujon; Philippe Rougier, Hôpital Européen Georges Pompidou, Paris; Pauline Ries, Institut Paoli Calmettes, Marseille; Marc Ychou, Institut Régional du Cancer Val d'Aurelle, Montpellier; Emilie Maillard, Fédération Francophone de Cancérologie Digestive; Laurent Bedenne, Centre Hospitalier Universitaire, Dijon; Thomas Aparicio, Hôpital Avicenne, Bobigny; Suzanne Nguyen, Hôpital Général, Beauvais; Ahmed Azzedine, Hôpital Général, Montélimard; Pierre-Luc Etienne, Clinique Armoricaine, Saint-Brieuc; Eveline Boucher, Centre Eugène Marquis, Rennes; Christine Rebischung, Hôpital A. Michallon, Grenoble; Olivier Bouché, Centre Hospitalier Universitaire Robert Debré, Reims, France.
Sorbonne Université · FR
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare epirubicin, cisplatin, and capecitabine (ECX) with fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatments in patients with advanced gastric or esophagogastric junction (EGJ) adenocarcinoma. PATIENTS AND
methodsThis open, randomized, phase III study was carried out in 71 centers. Patients with locally advanced or metastatic gastric or EGJ cancer were randomly assigned to receive either ECX as first-line treatment (ECX arm) or FOLFIRI (FOLFIRI arm). Second-line treatment was predefined (FOLFIRI for the ECX arm and ECX for the FOLFIRI arm). The primary criterion was time-to-treatment failure (TTF) of the first-line therapy. Secondary criteria were progression-free survival (PFS), overall survival (OS), toxicity, and quality of life.
resultsIn all, 416 patients were included (median age, 61.4 years; 74% male). After a median follow-up of 31 months, median TTF was significantly longer with FOLFIRI than with ECX (5.1 v 4.2 months; P = .008). There was no significant difference between the two groups in median PFS (5.3 v 5.8 months; P = .96), median OS (9.5 v 9.7 months; P = .95), or response rate (39.2% v 37.8%). First-line FOLFIRI was better tolerated (overall rate of grade 3 to 4 toxicity, 69% v 84%; P < .001; hematologic adverse events [AEs], 38% v 64.5%; P < .001; nonhematologic AEs: 53% v 53.5%; P = .81).
conclusionFOLFIRI as first-line treatment for advanced gastric and EGJ cancer demonstrated significantly better TTF than did ECX. Other outcome results indicate that FOLFIRI is an acceptable first-line regimen in this setting and should be explored as a backbone regimen for targeted agents.
Indexed as
AdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsCamptothecinCapecitabineCisplatinDeoxycytidineEpirubicinEsophagogastric JunctionFemaleFluorouracilFollow-Up StudiesFranceHumansIrinotecanLeucovorinMaleCamptothecinCapecitabineCisplatinDeoxycytidineEpirubicinFluorouracilIrinotecanLeucovorin
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT02870036ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.